American Heart Journal
Volume 156, Issue 4 , Pages 623-632, October 2008

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

  • Robert M. Califf, MD

      Affiliations

    • Duke Transitional Medicine Institute, Durham NC
    • Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: Robert M. Califf, MD, Duke Translational Medicine Institute, P.O. Box 17969, Durham, NC 27715.
    • ,
  • Mitradev Boolell, MD

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland
    • ,
  • Steven M. Haffner, MD

      Affiliations

    • University of Texas Health Science Center, San Antonio, TX
    • ,
  • M. Angelyn Bethel, MD

      Affiliations

    • Division of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, NC
    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • John McMurray, MD

      Affiliations

    • Department of Medicine, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK
    • ,
  • Anil Duggal, MD

      Affiliations

    • Novartis Pharma Corp, East Hanover, NJ
    • ,
  • Rury R. Holman, FRCP

      Affiliations

    • Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, UK
    • ,
  • for the NAVIGATOR Study Group

      Affiliations

    • See Appendix A for executive committee members. As chair of the trial, Dr Califf takes responsibility for the content of this article.

Received 12 May 2004; accepted 20 May 2008. published online 09 September 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study is funded by Novartis Pharma AG, Basel, Switzerland.

PII: S0002-8703(08)00389-X

doi:10.1016/j.ahj.2008.05.017

American Heart Journal
Volume 156, Issue 4 , Pages 623-632, October 2008

Article Tools

* Image Usage & Resolution